Connect Biopharma Holdings Ltd Stock Price, News & Analysis

Connect Biopharma (NASDAQ:CNTB) has partnered with former Cincinnati Bengals running back Ickey Woods and the Jovante Woods Foundation to expand a nationwide asthma education program. The initiative, launched on August 14, 2025, commemorates the death of Woods' 16-year-old son Jovante from an acute asthma attack in 2010.

The collaboration includes a video package featuring Jovante's story and will expand educational events across new U.S. markets during the 2025 NFL season. Connect Biopharma is currently conducting Phase 2 Seabreeze STAT studies for acute asthma exacerbations, with topline data expected in H1 2026.

According to CDC data, over 1 million people annually visit emergency departments for acute asthma exacerbations, with up to 30% requiring hospitalization. Approximately 50% experience worsening or new exacerbations within four weeks, and over 3,500 people die from asthma yearly in the U.S.

Connect Biopharma (NASDAQ:CNTB) reported Q2 2025 financial results and significant developments in its clinical programs. The company initiated Phase 2 Seabreeze STAT studies for rademikibart in asthma and COPD exacerbations, with topline data expected in H1 2026. Their partner Simcere submitted a new drug application to China's NMPA for rademikibart in atopic dermatitis treatment.

Financial highlights include cash position of $71.8 million as of June 30, 2025, expected to fund operations into 2027. The company reported a net loss of $12.9 million ($0.23 per share) for Q2 2025. Connect announced plans to terminate its ADR program and directly list ordinary shares on Nasdaq, aiming to improve institutional visibility and eliminate depositary fees.

Connect Biopharma (NASDAQ:CNTB) has appointed industry veteran Jim Schoeneck to its Board of Directors, expanding the board from six to seven members. Schoeneck brings over 40 years of experience in developing and commercializing breakthrough medicines.

Currently serving as Chairman of the Board for FibroGen, Inc. and Calidi Biotherapeutics, Schoeneck will contribute to advancing Connect's lead candidate rademikibart, which is being developed for acute exacerbations in asthma and COPD patients. The company expects clinical data from its Phase 2 Seabreeze STAT studies in the first half of 2026.

[ "Addition of experienced board member with 40+ years in biotech development and commercialization", "Strategic expertise in both organic and inorganic growth", "Relevant experience as Chairman of the National Board of Directors of the Asthma and Allergy Foundation of America" ]

Connect Biopharma (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced plans to terminate its American Depositary Receipt (ADR) program and directly list its ordinary shares on the Nasdaq Global Market. The transition is scheduled for September 2, 2025, with ADRs being exchanged for ordinary shares at a one-for-one ratio.

The company will maintain its current trading symbol "CNTB" after the transition. CEO Barry Quart emphasized that this move represents a strategic step toward becoming a U.S.-centric company, aiming to increase institutional visibility and eliminate ADR depositary fees. The company continues to advance its Phase 2 clinical development program for rademikibart in asthma and COPD treatment.

Connect Biopharma (NASDAQ:CNTB), a clinical-stage biopharmaceutical company specializing in inflammatory disease treatments, has announced its participation in the BTIG Virtual Biotechnology Conference. The company's management will engage in a fireside chat on Tuesday, July 29th, 2025 at 9:20 a.m. ET.

Investors can access the live webcast through Connect's website in the Investors section under Presentations, Events & News at investors.connectbiopharm.com. A replay will remain available for approximately 90 days after the event.

Connect Biopharma (NASDAQ: CNTB), a clinical-stage biopharmaceutical company specializing in inflammatory disease treatments, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq's Listing Qualifications Department on July 16, 2025, verifying that its American Depositary Shares (ADSs) maintained a closing bid price of at least $1.00 for 10 consecutive business days as of July 15, 2025.

This development ensures CNTB's continued listing and trading on the Nasdaq exchange, with the compliance matter now resolved.

Connect Biopharma (NASDAQ:CNTB) announced that its Chinese partner Simcere Pharmaceutical has submitted a New Drug Application (NDA) to China's NMPA for rademikibart, targeting atopic dermatitis treatment in adults and adolescents.

The submission follows a 2023 exclusive licensing agreement where Simcere acquired rights to develop, manufacture, and commercialize rademikibart in Greater China. Connect remains eligible for up to $110 million in milestone payments plus tiered royalties up to low double-digit percentages on net sales. The opportunity is significant, with an estimated 70 million atopic dermatitis patients in China.

Connect Biopharma presented clinical data for rademikibart, their investigational anti-IL-4Rα antibody, at EAACI 2025. The Phase 2b trial results showed significant improvements in lung function and asthma control for patients with eosinophilic-driven type 2 asthma. Rademikibart demonstrated rapid improvement in prebronchodilator FEV1 from Week 1, sustained through 24 weeks. The drug achieved notable reductions in annualized asthma exacerbation rates: 63% in patients with elevated baseline eosinophils, 69% in elevated FeNO patients, and 74% in those with both markers elevated. The company expects to report topline data from ongoing Phase 2 acute exacerbation studies in asthma and COPD in the first half of 2026.

Connect Biopharma (Nasdaq: CNTB) announced two oral presentations scheduled for the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress in Glasgow, UK. Dr. Rekha Chaudhuri will present findings on their drug Rademikibart, focusing on its effects in treating eosinophilic-driven, Type 2 asthma. The first presentation will discuss reduction in annualized exacerbations, while the second will cover improvements in lung function. Both presentations are scheduled for June 13th, 2025, from 3:00-4:30 PM BST. The presentations will later be available on Connect's website under the presentations and publications section.